Introduction
Several clinical trials have confirmed the efficacy of oxcarbazepine (OXC) monotherapy in partial seizures with or without secondary generalization, and in generalized tonic-clonic seizures. [1] [2] [3] [4] [5] [6] To date, long-term experience with OXC has been reported in only two studies, which included mainly chronic patients switched over to OXC due to problems with tolerance or inefficacy of a previous antiepileptic drug (AED). 7, 8 In this retrospective study we assessed the long-term outcome of OXC monotherapy by determining the retention rate for the treatment. This parameter represents a composite of both efficacy and tolerance of a drug.
Methods
We retrospectively screened all adult epileptic patients (aged at least 16 years) who attended the outpatient clinic of the Department of Neurology at Tampere University Hospital.
We identified 97 patients (51 men, 46 women) who had used OXC as first monotherapy (Group I), and 78 patients (36 men, 42 women, Group II) who had used OXC as alternative monotherapy. The reasons for shifting from a previous AED monotherapy to OXC were adverse effects in 32 patients (41%), inadequate efficacy in 21 patients (27%), a Summary In a retrospective study we assessed the outcome of oxcarbazepine (OXC) monotherapy in a naturalistic setting. We identified all adult patients who had been treated with OXC at a single neurological outpatient center. A total of 175 patients were identified, 97 of them used OXC as their first AED (Group I), and 78 as second monotherapy (Group II), after failure of a previous AED. The 1-year retention rates of OXC treatment were 91% for Group I and 77% for Group II. Discontinuations were due to adverse effects in 3 patients (3%) in Group I and in 11 patients (14%) in Group II, and due to lack of efficacy in 2 patients (2%) in Group I and in 6 patients (8%) in Group II. We conclude that OXC monotherapy is effective and well tolerated. combination of these causes in 13 patients (17%) and other reasons in 12 patients (15%).
Cox proportional hazards model was used with time to discontinuation as the outcome. Follow-up started at introduction of OXC medication and ended at discontinuation of treatment or closing date. Retention rate (i.e. proportion of patients continuing OXC medication) and its 95% confidence interval were estimated using the Kaplan-Meyer method. 9 The study was approved by the Ethics committee of the Tampere University Hospital. Fig. 1) . At least 1-year follow-up data were available for 68 patients of Group I and for 46 patients of Group II. At 1 year, 41/68 (60%) of patients of Group I and 10/46 (22%) of Group II remained seizure free after the start of OXC treatment.
Results

Retention rates for
The mean daily maintenance doses of OXC were 840 mg (median 600 mg, range 300-2400 mg) in Group I and 1040 mg (median 900 mg, range 150-2400 mg) in Group II.
The number of seizure-free patients with different daily doses of OXC is shown in Fig. 2 .
OXC treatment was withdrawn in nine of the cases (9%) in Group I, in two cases due to lack of efficacy, in three cases due to adverse effects, and in four cases due to other reasons. In Group II, OXC was discontinued in 20 cases (26%), in six cases due to lack of efficacy, in eleven cases due to adverse effects, and in three cases due to other reasons.
Discussion
The outcome of initial OXC monotherapy was favorable; the 1-year retention rate was 91%, and 60% of the previously untreated patients, followed up for at least one year, remained seizure free while on OXC. These findings concur with those observed in clinical trials. 2, 3 Most of the newly diagnosed patients used doses which are lower than the recommended target dose range, 900-1200 mg/day. 10 In fact, most of the seizure-free patients were on doses 900 mg/day, and on the other hand, none of the patients on doses higher than 1500 mg/day became seizure free. The safety and tolerance of first monotherapy with OXC were good; the frequency of discontinuation of treatment due to adverse effects (3%) was even lower than that observed in monotherapy trials (3.5-12%). [1] [2] [3] Only a minority of the patients failing on the first monotherapy due to inadequate control of seizures will have a good outcome on the second monother- apy. 11 However, many of the patients who have experienced idiosyncratic reactions or intolerable adverse effects to a previous AED may have a favorable outcome on the substituted monotherapy. 11 In our experience, OXC was efficacious and well tolerated in most of the patients who shifted to OXC after failure of a previous AED. However, the percentage of patients who became seizure free (22%) was much smaller than in patients on initial OXC monotherapy.
In conclusion, the present retrospective survey of an unselected outpatient population suggests that OXC monotherapy is an effective and well tolerated option for adult patients with partial and generalized tonic-clonic seizures. Our findings suggest that many patients may have an excellent response to OXC as monotherapy at doses lower than usually recommended, and that only a limited number of patients benefit from doses higher than 1500 mg/day.
